"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."

Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) HONG KONG,